(MENAFN- GlobeNewsWire - Nasdaq) AI-driven screening, demand for affordable therapies, and unmet needs in rare, infectious and neurodegenerative diseases are accelerating drug repurposing and CRO opportunities.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Global Drug Repurposing Market to Reach $58.33 Billion by 2030 as AI Accelerates Therapeutic Discovery
The global drug repurposing market is experiencing strong growth as pharmaceutical and biotechnology organizations seek faster, more cost-effective ways to develop treatments. The market is projected to increase from $37.38 billion in 2025 to $40.95 billion in 2026, representing a compound annual growth rate (CAGR) of 9.6%. Historical growth has been supported by the high cost and lengthy timelines associated with traditional drug discovery, the increasing number of unsuccessful drug candidates, the rising prevalence of chronic and rare diseases, and limited treatment options for emerging health threats. Early adoption of computational drug repositioning methods has also contributed to market expansion.
Looking ahead, the drug repurposing market is forecast to reach $58.33 billion by 2030, expanding at a CAGR of 9.2%. Growth is expected to be driven by the integration of artificial intelligence and machine learning into drug discovery, increased investment in pharmaceutical and biotechnology research, and the expansion of contract research organization capabilities. Demand for affordable therapies and regulatory support for repurposed drug approvals are also expected to strengthen the market outlook.
Key drug repurposing market trends include greater use of phenotypic and target-based screening, increased adoption of structure-based drug repositioning, and expanded identification of off-target drug activity. Researchers are also applying repurposing strategies more extensively to rare diseases, infectious diseases, oncology, and neurological conditions. By working with molecules that already have established development histories, organizations can potentially shorten research timelines and improve the efficiency of therapeutic development.
The rising incidence of neurodegenerative diseases is anticipated to be a major driver of drug repurposing market growth. Longer life expectancy is increasing the number of people affected by age-related neurological conditions, including Alzheimer's dementia. Repurposing established medicines allows researchers to investigate compounds with existing safety and pharmacological data against disease pathways associated with neurodegeneration, supporting the faster development of potential therapies.
According to the Alzheimer's Association, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia in 2023. That figure is projected to reach 13.8 million by 2060. This growing disease burden is increasing the need for innovative treatment strategies and encouraging pharmaceutical developers, academic researchers, and technology companies to assess existing compounds for new neurological applications.
Artificial intelligence is becoming increasingly important within the drug repurposing industry. Market participants are investing in AI-driven drug-protein interaction modeling to identify new therapeutic applications for existing medicines and analyze biological relationships across large datasets. These technologies can support more targeted candidate selection, improve research productivity, and accelerate preclinical decision-making.
In July 2025, Cosmos Health Inc. launched Cloudscreen 2.0, an advanced AI platform developed to support drug repurposing research. The platform can process datasets more than 100 times larger than earlier versions and enables detailed analysis of drug-protein interactions. It also incorporates mutagenesis data and tools for studying disordered proteins, with potential applications across cancer, obesity, and diabetes research. GPU-based cloud computing provides scalable processing capabilities designed to support broader research and development pipelines.
Strategic financing and collaboration are also shaping the competitive environment. In July 2025, Predictive Oncology Inc. entered into a partnership with YA II PN, Ltd. and secured a $10 million share purchase agreement. Predictive Oncology plans to use the collaboration to advance its AI-enabled platform, accelerate the identification of new uses for existing drugs, and streamline oncology drug discovery workflows.
North America was the largest region in the drug repurposing market in 2025, supported by established pharmaceutical research infrastructure, investment in artificial intelligence, and a strong biotechnology ecosystem. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The global market coverage includes Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Type: Disease-Centric; Target-Centric; Drug-Centric
2) By Drug Molecules: Biologics; Small Molecule
3) By Therapeutic Area: Oncology; Neurology; Infectious Diseases; Cardiovascular Diseases; Autoimmune Disorders
4) By Route Of Administration: Oral; Intravenous; Topical; Inhalation; Intramuscular
5) By End-User: Pharmaceutical Companies; Research And Academic Institutes; Contract Research Organizations
Subsegments:
1) By Disease-Centric: Phenotypic Screening; Epidemiological Analysis; Clinical Observation-Based Repurposing
2) By Target-Centric: Protein Target Modulation; Pathway Modulation; Biomarker-Based Targeting
3) By Drug-Centric: Off-Target Activity Identification; Structure-Based Drug Repositioning; Adverse Effect-Based Repurposing
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment